Janux Therapeutics (JANX) vs Latigo Biotherapeutics (LTGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Janux Therapeutics is the larger company by market cap ($1.13 billion vs $980.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JANX | LTGO |
|---|---|---|
| Share price | $18.50 | $14.79 |
| Market cap | $1.13B | $980.57M |
| 1-day change | +3.24% | -4.70% |
| YTD return | +34.06% | — |
| 1-year return | -23.55% | — |
| 5-year return | -12.45% | — |
| EPS (TTM) | $-1.64 | $-2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.34 | $25.93 |
| 52-week low | $12.12 | $14.60 |
| Distance from 52-week high | -47.65% | -42.96% |
| Analyst consensus | none | none |
| Avg. price target upside | +95.89% | +253.28% |
| Average volume | 845.95K | 391.26K |
| Shares outstanding | 61.14M | 66.30M |
| Employees | 113 | 66 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Janux Therapeutics in Healthcare and Latigo Biotherapeutics in Health Care.
About Janux Therapeutics
JANX stock →Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
Healthcare · Biotechnology · 113 employees
About Latigo Biotherapeutics
LTGO stock →Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction.
Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees
JANX vs LTGO FAQ
Which is bigger, Janux Therapeutics or Latigo Biotherapeutics?
Janux Therapeutics (JANX) is larger, with a market capitalization of $1.13B compared with $980.57M for Latigo Biotherapeutics (LTGO).
Are Janux Therapeutics and Latigo Biotherapeutics in the same industry?
No. Janux Therapeutics is in the Healthcare sector, while Latigo Biotherapeutics is in Health Care.